Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francine Foss

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
Nature Reviews. Clinical Oncology|April 7, 2011
Hematology: relapsed and refractory PTCL--into the therapeutic abyssFrancine Foss
Current Opinion in Oncology|August 18, 2004
Mycosis fungoides and the Sézary syndromeFrancine Foss
Therapeutic Advances in Hematology|April 5, 2013
Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyondFrancine Foss
Clinical Advances in Hematology & Oncology : H&O|January 14, 2010
Advances in the treatment of T-cell lymphomasFrancine Foss
Seminars in Oncology|March 7, 2006
Clinical experience with denileukin diftitox (ONTAK)Francine Foss
Leukemia & Lymphoma|June 19, 2004
Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approachesFrancine Foss
Seminars in Oncology|March 7, 2006
Immunomodulatory effects of rexinoidsFrancine Foss
Blood|August 1, 2002
Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitoxGullu Gorgun, Francine Foss
Seminars in Oncology|March 7, 2006
CTCL: the most common type of primary cutaneous lymphoma: introductionFrancine Foss, Sean Whittaker
Current Hematologic Malignancy Reports|April 29, 2010
Cutaneous T-cell lymphoma: Biologic targets for therapyJaehyuk Choi, Francine Foss
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Nature Reviews. Clinical Oncology|April 7, 2011
Hematology: relapsed and refractory PTCL--into the therapeutic abyssFrancine Foss
Current Opinion in Oncology|August 18, 2004
Mycosis fungoides and the Sézary syndromeFrancine Foss
Therapeutic Advances in Hematology|April 5, 2013
Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyondFrancine Foss
Clinical Advances in Hematology & Oncology : H&O|January 14, 2010
Advances in the treatment of T-cell lymphomasFrancine Foss
Seminars in Oncology|March 7, 2006
Clinical experience with denileukin diftitox (ONTAK)Francine Foss
Leukemia & Lymphoma|June 19, 2004
Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approachesFrancine Foss
Seminars in Oncology|March 7, 2006
Immunomodulatory effects of rexinoidsFrancine Foss
Blood|August 1, 2002
Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitoxGullu Gorgun, Francine Foss
Seminars in Oncology|March 7, 2006
CTCL: the most common type of primary cutaneous lymphoma: introductionFrancine Foss, Sean Whittaker
Current Hematologic Malignancy Reports|April 29, 2010
Cutaneous T-cell lymphoma: Biologic targets for therapyJaehyuk Choi, Francine Foss
Pageof 12